These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9645341)

  • 1. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
    Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
    Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
    Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
    Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CD44 in non-Hodgkin's lymphoma.
    Ristamäki R; Joensuu H; Jalkanen S
    Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Origin and function of circulating CD44 in non-Hodgkin's lymphoma.
    Ristämaki R; Joensuu H; Grön-Virta K; Salmi M; Jalkanen S
    J Immunol; 1997 Mar; 158(6):3000-8. PubMed ID: 9058839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
    Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
    Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteopontin and CD44 levels in lymphoreticular malignancies in children.
    Elli M; Dagdemir A; Bozkurt C; Pinarli FG; Duzgun A; Ozmen ZC; Ertem U; Acar S
    Bratisl Lek Listy; 2012; 113(9):534-8. PubMed ID: 22979908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.
    Ristamäki R; Joensuu H; Söderström KO; Jalkanen S
    J Pathol; 1995 Jul; 176(3):259-67. PubMed ID: 7545748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum CD44 measurement in malignant lymphoma.
    Fukuda Y
    Kurume Med J; 2001; 48(1):65-9. PubMed ID: 11402623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum copper.
    Hisamitsu S; Shibuya H; Hoshina M; Horiuchi J
    Acta Oncol; 1990; 29(7):879-83. PubMed ID: 2261202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
    Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
    Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P; Teerenhovi L; Joensuu H
    Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma.
    Harabuchi Y; Kataura A; Imai K
    Ann Otol Rhinol Laryngol; 1996 Aug; 105(8):634-42. PubMed ID: 8712635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
    Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
    Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.